Advanced search
Start date
Betweenand


Cytomorphometric Evaluation of Oral Mucosa of Patients with Duchenne Muscular Dystrophy

Full text
Author(s):
Macedo, Debora S. ; Jacomo, Thierry S. ; Moraes, Bruna ; Ortega, Karem L. ; Braz-Silva, Paulo H. ; Zonta, Marco A. ; Pallos, Debora ; Martins, Fabiana
Total Authors: 8
Document type: Journal article
Source: Head and Neck Pathology; v. N/A, p. 4-pg., 2022-01-22.
Abstract

Duchenne muscular dystrophy (DMD) is a rare genetic disorder in which patients progressive muscle deterioration and low life expectancy. Since DMD has no cure, treatment slows the deterioration process using corticosteroids and other medications, including oral bisphosphonates (BP). These drugs can lead to toxicities in both soft and hard tissues. The objective of this study was to present cytological changes in DMD patients, comparing to young, healthy individuals. Cytological smears were obtained from buccal mucosa from nine DMD patients and five healthy patients. The Papanicolaou technique was used to stain the slides. Images were captured using a photomicroscope, and 50 clearly defined cells were selected. The size and ratio between the nucleus and cytoplasmic areas (NA/CA) diameter were measured using a computer program. All the DMD patients presented a statistical difference (p < 0.0001) in the size of the cytoplasm (0.60 +/- 0.33 mu m) and the NA/CA ratio (0.17 +/- 0.07 mu m) was seen when compared to the control group (cytoplasm 0.60 +/- 0.15 mu m and nucleus 0.14 +/- 0.05 mu m). Furthermore, in one DMD in use of BP who presented Medication-Related Osteonecrosis of the Jaw (MRONJ), presented higher differences in the cytoplasmic (1.20 +/- 0.65 mu m) and nuclear (0.20 +/- 0.12 mu m) sizes (p < 0.0001) compared with all others DMD patients. These results suggest that the drugs used or the systemic condition of individuals with DMD may contribute to these changes. (AU)

FAPESP's process: 18/02568-8 - Characterization, study of cytokines and virus infections in stomatitis lesions related to the use of mTOR inhibitors in renal transplant patients.
Grantee:Fabiana Martins e Martins de Oliveira
Support Opportunities: Regular Research Grants